| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2024 Q2 | Aug 6, 2024 | Long Cast Advisers | 6.0% | 16.0% | CCRD, ENVX, MAMA, MTRX, PESI, RELL, RSSS, SOTK | Concentration, Construction, Research, small caps, value | The fund focuses on small and under-owned companies with long and wide opportunity pathways. The manager looks for companies that enable ample room for compounding and can withstand market conditions without terminal value destruction. The concentrated portfolio is positioned with companies that meet this profile. | RSSS MTRX |
View |
| 2025 Q2 | Aug 27, 2025 | Long Cast Advisers | 19.0% | -4.0% | CCRD, EEFT, MAMA, MTRX, PDEX, PESI, QRHC, RELL, RSSS | Cash, Demand Destruction, Microcaps, payments, small caps, Trade Policy, Valuations | Manager focuses on small company investing with concentrated positions in microcaps and small caps. Portfolio includes companies like CCRD, QRHC, MTRX, and RSSS with emphasis on finding undiscovered stocks trading at cheap valuations relative to expected growth and cash flow. | QRHC EEFT CCRD QRHC CCRD |
View |
| 2025 Q1 | Jun 5, 2025 | Long Cast Advisers | -20.0% | -20.0% | CCRD, GOOG, META, MTRX, PDEX, PESI, QRHC, RSSS | Concentration, Long Term, Outperformance, Price Discovery, small caps, value | Manager focuses exclusively on small company investing, seeking five-year doubles with 15% annualized returns. Portfolio concentrated in top-five positions representing 70% of holdings, with three stocks at or around 15% weightings. | PESI QRHC MTRX RSSS PDEX CCRD |
View |
| 2024 Q1 | May 7, 2024 | Long Cast Advisers | 6.0% | 16.0% | CCRD, CCRN, CTEK, DAIO, ENVX, LRCX, MTRX, PESI, PSSR, QRHC, RELL, RSSS, SNES | concentrated, Cyclical, Fundamental Analysis, small caps, Turnarounds, value | Manager focuses exclusively on small companies that are barely included in any indices, using fundamental analysis to evaluate financial statements and corporate strategies. The concentrated approach targets well-researched small companies offering compelling opportunities for high returns through long-term cash earnings analysis. | View | |
| 2024 Q1 | Apr 15, 2024 | Weitz Partners III Opportunity Fund | 9.1% | 14.1% | AAPL, AMZN, BRK-B, CCRD, CHTR, FIS, GOOG, GS, LBRDA, LBTYK, META, MKL, MSFT, PRM, SPY | Broadband, Long/Short, Magnificent Seven, multi-cap, technology, value | The fund focuses on valuation-driven investment decisions, trimming positions like Meta Platforms, Microsoft and Amazon based on valuation considerations. The managers emphasize their multi-cap approach to finding undervalued businesses across all market capitalizations. | View | |
| 2023 Q3 | Oct 31, 2023 | Long Cast Advisers | 6.0% | 16.0% | AIM, CCRD, DAIO, MAMA, MTRX, PDEX, QHRC, RELL, RSSS, SANW, SNES, SOTK | Concentration, Manufacturing, Medical Devices, Quality, small caps, value | Manager focuses exclusively on small company investing with a research-intensive approach. Portfolio consists of small, customer-centric companies run by smart, humble managers who iterate towards better solutions. Small caps are currently discounted due to rising rates as they have more vulnerabilities than larger companies. | SOTK PDEX |
View |
| 2024 Q3 | Oct 25, 2024 | Long Cast Advisers | 6.0% | 16.0% | AAPL, BANC, CCRD, ENVX, GS, JPM, MTRX, PDEX, PESI, QRHC, SNES | Concentration, Medical Devices, payments, small caps, value | PDEX is a contract manufacturer to the medical device industry with a marquee torque limiting driver for orthopedic and maxillofacial surgeries. The company recently completed manufacturing expansion and now has capacity for $80M-$100M in sales, up from under $40M in FY21. Management is patient and thoughtful with a long-term approach. | CCRD PDEX |
View |
| 2025 Q4 | Jan 24, 2026 | Long Cast Advisers | 1.0% | 0.0% | CCRD, CCRN, EEFT, LSYN, MAMA, MTRX, NRC, PDEX, PESI, QRHC, RELL, RSSS | healthcare, Owner-Operator, small caps, Staffing, value | Significant focus on healthcare staffing through CCRN investment, with nurse staffing industry facing competitive pressures but potential for margin improvement. Also invested in NRC, a healthcare consulting and patient survey company with strong margins despite industry headwinds. Portfolio concentrated in small and micro-cap companies with intent to own for multiple years. Manager emphasizes patient capital approach targeting 15% annualized returns through well-researched small company investments. Focus on companies trading at attractive valuations with strong balance sheets and cash positions. CCRN example shows investment in company with 40% of market cap in cash and low enterprise value multiples. | RSSS MTRX NRC CCRN |
View |
| 2023 Q3 | Aug 11, 2023 | Weitz Partners III Opportunity Fund | 9.1% | 14.1% | AMZN, BKI, BRK-B, CCRD, CSGP, FIS, FTRE, GOOG, GS, KMX, LBRDA, LH, LSXMK, LYV, META, MSFT, PRM, QRTEP, SCHW, SIRI | efficiency, Media, Quality, technology, Tracking Stocks, value | The managers emphasize owning high-quality, durable businesses led by talented management teams capable of navigating uncertain times and potentially coming out stronger. They believe companies with competitive advantages, smart and flexible management teams, and solid finances will always find ways to move forward and build business value. | View | |
| 2023 Q1 | Aug 5, 2023 | Long Cast Advisers | 6.0% | 16.0% | CCRD, CCRN, DAIO, ENVX, MTRX, PESI, SOTK, TBTC | Construction, energy, nuclear, small cap, turnaround, value | PESI operates one of only three DOE-licensed facilities for low-level nuclear waste treatment. The company has potential to significantly expand through processing Hanford cleanup waste via grouting at their Northwest facility, with regulatory approvals received in early 2023. | MTRX PESI |
View |
| 2024 Q2 | Jul 28, 2024 | Weitz Partners III Opportunity Fund | 9.1% | 14.1% | AAPL, AMZN, AON, BRK-B, CCRD, CSGP, FIS, GOOG, GPN, IEX, KMX, LBRDA, LLYVA, LSXMK, LYV, MA, META, MSFT, NVDA, ODFL, PRM, SIRI, TXN | Long/Short, Mega Cap, Multi Cap, technology, value | AI initiatives have captivated investors' interest as companies like Alphabet, Amazon, and Meta are at the forefront of developing and deploying artificial intelligence in consumer and business applications. While AI development drives investor enthusiasm, these companies' traditional businesses continue to outperform and generate significant cash flow. | View | |
| 2023 Q2 | Jun 30, 2023 | Long Cast Advisers | 6.0% | 16.0% | CCRD, DAIO, ENVX, MMMB, MTRX, PESI, RELL, SIFY | Concentration, small caps, value | View | ||
| 2023 Q4 | Feb 13, 2024 | Long Cast Advisers | 6.0% | 16.0% | CCRD, DAIO, MAMA, MTRX, PDEX, QHRC, RELL, RSSS, SOTK | Concentration, Manufacturing, Medical Devices, small caps, value | PDEX operates as a contract manufacturer in the medical device space, producing battery-powered handheld drivers for surgeons. The company has doubled its manufacturing capacity and secured a large order doubling its backlog to $41M, suggesting strong growth potential for FY24. | SOTK PDEX |
View |
| 2024 Q4 | Jan 29, 2025 | Weitz Partners III Opportunity Fund | 1.1% | 15.4% | AMZN, BRK-A, CCRD, CHTR, CSGP, DHR, FIS, GOOGL, GPN, LBRDA, MA, META, MSFT, PRM, ROP, SIRI, TECH, TMO, TXN, V | Life Sciences, Long/Short, Megacap, payments, technology, value | Investor enthusiasm around artificial intelligence drove outsized returns on a handful of megacap tech stocks. While the fund stayed true to its investment philosophy and avoided chasing trends, many portfolio companies are actively exploring AI applications to enhance their operations and drive long-term growth. | View | |
| 2023 Q4 | Jan 27, 2024 | Weitz Partners III Opportunity Fund | 9.1% | 14.1% | AMZN, BRK-B, CCRD, CHTR, CSGP, FIS, GOOG, GPN, GS, KMX, LBRDA, LSXMK, META, MKL, MSFT, PRM, QRTEP, ROP, SCHW, SIRI, SPY, V | large cap, Long/Short, Media, payments, technology, value | The fund initiated a new position in Global Payments, a leading provider of payments acceptance services with roughly four million merchant locations worldwide. Despite increased competition in the payments landscape, the managers believe Global Payments is more durable than feared and trades at a compelling valuation. | CGPN.L LBRDA 4IMPRINT CCRD |
View |
| 2024 Q4 | Jan 24, 2025 | Long Cast Advisers | 20.0% | 39.0% | CCRD, MTRX, PDEX, PESI, QRHC, RSSS | Concentration, Industrial, Microcap, Price Discovery, small caps, value | Manager focuses exclusively on small company investing, seeking five-year doubles with 15% annualized returns. Portfolio concentrated in top-five positions representing 70% of assets. Believes small cap managers handily beat relevant indices due to over-representation of unprofitable lottery tickets in benchmarks and sparse analyst coverage creating opportunities. | PESI QRHC MTRX RSSS PDEX CCRD |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | Fund Letters | Weitz Partners III Opportunity Fund | CoreCard Corp. | Information Technology | Data Processing & Outsourced Services | Bull | NASDAQ | Apple Card, credit cards, Entrepreneurial management, financial technology, Goldman Sachs, Partnership Transition, payment processing | View Pitch |
| Apr 13, 2026 | Fund Letters | Long Cast Advisers | CoreCard Corporation | Information Technology | Data Processing & Outsourced Services | Bull | NYSE | acquisition target, Apple Card, Credit Card Processing, digital payments, financial technology, Fintech, Payment Platform | View Pitch |
| Apr 13, 2026 | Fund Letters | Long Cast Advisers | CoreCard Corporation | Information Technology | Data Processing & Outsourced Services | Bull | NYSE | Apple Card, Contract Extension, credit card services, Data Processing, financial technology, Goldman Sachs, regulatory environment | View Pitch |
| Apr 13, 2026 | Fund Letters | Long Cast Advisers | CoreCard Corporation | Software & Services | Systems Software | Bull | NYSE | Apple Card, Credit Card Technology, debt-free, Fintech, Goldman Sachs, payment processing, Share Buybacks, Software Licensing | View Pitch |
| Apr 13, 2026 | Fund Letters | Long Cast Advisers | CoreCard Corporation | Information Technology | Data Processing & Outsourced Services | Bull | NYSE | Apple Card, Contract Extension, credit card services, Data Processing, financial technology, Goldman Sachs, regulatory environment | View Pitch |
| Jan 8, 2026 | Fund Letters | Avram Fisher | CoreCard Corporation | Information Technology | Data Processing & Outsourced Services | Bull | New York Stock Exchange | acquisition, cross-selling, Fintech, Merger Arbitrage, Payments | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||